Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
Public ClinicalTrials.gov record NCT07226791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair
Study identification
- NCT ID
- NCT07226791
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- AGN-151607-DP Drug
- Placebo for AGN-151607-DP Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2026
- Primary completion
- Aug 31, 2028
- Completion
- Apr 30, 2030
- Last update posted
- May 18, 2026
2026 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CARI Clinical Trials INC /ID# 278844 | Riverside | California | 92504 | Recruiting |
| University of Florida - Jacksonville /ID# 261992 | Jacksonville | Florida | 32209 | Recruiting |
| Medical Research Center /ID# 278680 | Miami | Florida | 33144 | Recruiting |
| NorthShore University-Endeavor Health Evanston Hospital /ID# 277995 | Evanston | Illinois | 60201 | Recruiting |
| Integrity Clinical Research /ID# 278710 | Wichita | Kansas | 67202 | Completed |
| Novant Health New Hanover Regional Medical Center /ID# 261979 | Wilmington | North Carolina | 28401-7407 | Recruiting |
| Cleveland Clinic - Cleveland /ID# 277914 | Cleveland | Ohio | 44195 | Recruiting |
| Baylor University Medical Center /ID# 261955 | Dallas | Texas | 75246 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07226791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07226791 live on ClinicalTrials.gov.